Idasanutlin

(RG7388)

Breast
  • Phase
  • III
  • II
  • I
Gastrointestinal
  • Phase
  • III
  • II
  • I
Genitourinary
  • Phase
  • III
  • II
  • I
Gynecologic
  • Phase
  • III
  • II
  • I
Hematologic
  • Phase
  • III
  • II
  • I
Lung
  • Phase
  • III
  • II
  • I
Melanoma
  • Phase
  • III
  • II
  • I
Solid Tumor
  • Phase
  • III
  • II
  • I

This compound and its uses are investigational and have not been approved by the US Food and Drug Administration. Efficacy and safety have not been established. The information presented should not be construed as a recommendation for use. The relevance of findings in preclinical studies to humans is currently being evaluated.

Idasanutlin, an MDM2 antagonist

Idasanutlin, an investigational Nutlin family MDM2 antagonist, is currently in clinical development based on its potential for enhanced binding specificity. In preclinical studies, idasanutlin was shown to reduce tumor volume in murine xenograft models.1 Idasanutlin continues to be investigated in ongoing clinical studies.

1 Idasanutlin is an investigational small molecule currently being studied for its potential to inhibit the interaction of MDM2 with p53.1

Idasanutlin image: an investigational small molecule currently being studied for its potential to inhibit MDM2 interaction with p53

 

2 Idasanutlin is designed to bind to MDM2 in order to potentially prevent the p53-MDM2 interaction. This may result in the activation of p53.1

Idasanutlin image: designed to bind to MDM2 to potentially prevent p53-MDM2 interaction, which may activate p53

 

3 Preclinical data have shown that idasanutlin induced apoptosis, as measured by in vitro studies.1 Idasanutlin continues to be investigated in ongoing clinical studies.

Idasanutlin image: induced apoptosis as measured by in vitro studies

References

  1. Ding Q, Zhang Z, Liu JJ, et al. Discovery of RG7388, a potent and selective p53-MDM2 inhibitor in clinical development. J Med Chem. 2013;56:5979-5983. PMID: 23808545